Cytokinetics, Incorporated

NASDAQ:CYTK

Biotechnology

Healthcare
$51.32 +3.86%

+$2.90 today

Market cap
$7.15B
Beta
0.43
P/E (TTM)
-11.6
EPS (TTM)
-$6.73
52W Low $31.99High $80.20

Volume 1.59M

Average 2.37M

CYTK Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Cytokinetics, IncorporatedNASDAQ: CYTK

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit declines year over year

Q2 FY2026 gross profit of $29.18M fell 56.3% year over year, behind the -26.5% change in trailing-twelve-month gross profit. Sequentially, it rose 72.0% from the prior quarter.

Context

  • Gross profit amounted to 88.5% of revenue in FY2025, down 1648.7 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -56.3% toward the trailing-twelve-month pace of -26.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$29.18M+72.0% QoQ
Last fiscal yearDec 2025
$77.91M+124.3% YoY
LTMJun 2026
$62.98M-26.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-56.3%——
1 year+124.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
77.91M USD
Year-over-year change
+124.3%

Gross Profit vs competitors

How CYTK compares with its peers on the latest reported figures

  • CYTK's LTM Jun 2026 gross profit of $62.98M is the highest of the 3 companies compared; the peer median is $9.47M.
  • Its year-over-year change of -26.5% is the lowest of 2, against a peer median of +115.4%.
  • Gross profit amounts to 88.7% of revenue for CYTK, versus a peer median of 122.4%.
CYTK Competitors Peer median
Gross Profit for CYTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYTKCytokinetics, IncorporatedLTM Jun 2026$62.98M -26.5%—88.7%
RNAAtrium Therapeutics, Inc.FY2025$18.62M ——100.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$326K +115.4%—144.9%
KARDKardigan, Inc.—— ———
Peer median (excluding CYTK) $9.47M+115.4%—122.4%

Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue70.43M94.59M7.53M18.47M88.04M
Cost of Revenue159.94M240.81M330.12M339.41M10.13M
Gross Profit(89.51M)(146.23M)(322.59M)(320.93M)77.91M
Gross Margin-127.1%-154.6%-4284.1%-1737.2%88.5%
Research & Development159.94M240.81M330.12M339.41M405.9M
Selling, General & Admin96.8M177.98M173.61M215.31M284.27M
Operating Expenses96.8M177.98M173.61M215.31M690.17M
Depreciation & Amortization2.28M5.81M11.89M9.53M10.13M
EBITDA(183.71M)(331.99M)(456.68M)(493.48M)(774.83M)
EBITDA Margin-260.8%-351.0%-6064.9%-2671.2%-880.1%
Operating Income(186.31M)(324.2M)(496.21M)(536.25M)(612.26M)
Operating Margin-264.5%-342.8%-6589.7%-2902.7%-695.4%
Interest Income331K11.34M27.63M51.53M48.42M
Interest Expense29.33M51.16M57.67M86.51M103.87M
Other Income / Expenses(29M)(64.75M)(30.04M)(53.28M)(172.7M)
Income Before Tax(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Pre-Tax Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
Income Tax Expense00000
Net Income(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Net Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
EPS (Basic)(2.80)(4.33)(5.45)(5.26)(6.54)
EPS (Diluted)(2.80)(4.33)(5.45)(5.26)(6.54)
Weighted Avg Shares76.89M89.83M96.52M111.98M120.02M
Weighted Avg Shares (Diluted)76.89M89.83M96.52M111.98M120.1M

Cytokinetics, Incorporated

NASDAQ:CYTK

Intrinsic Alpha fair value

Locked

Current Price

$51.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.